Restek Appoints New CEO
Bill Arrowsmith takes over for Bryan Wolcott, who retired from the position at the end of last year.
Restek Corporation, a provider of chromatography consumables, has announced the retirement of Bryan Wolcott, president and CEO, on December 31, 2023. With over 26 years of dedicated service, Wolcott served as Restek’s chief executive starting back in 2010, according to a press release from the company. He will remain a member of Restek’s Board of Directors.
Bill Arrowsmith will take over as the company’s CEO. Arrowsmith joined Restek back in 2017, when he served as the company’s chief financial officer before taking on the role of general manager in January 2023. As chief executive, Arrowsmith will be tasked with driving Restek's growth and development.
Prior to joining Restek, Arrowsmith held various finance and general management positions with companies such as Ernst & Young, AMETEK, and PwC. He holds a BS degree in accounting and international business from Pennsylvania State University and an MBA from Cornell University.
Restek is headquartered in Bellefonte, Pennsylvania. Founded in 1985, it has established officers in Japan, Germany, China, France, Italy, and United Kingdom. Restek is a provider of manufacturing and distributing high-quality instrument consumables, chromatography columns, sample preparation materials, scientific supplies, and reference standards.
This article was written with the help of artificial intelligence and has been edited to ensure accuracy and clarity. You can read more about our policy for using AI here.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
